Manchester, UK – The first patient in the UK has been treated with a pioneering new investigational gene therapy designed to treat the debilitating genetic disorder Gaucher disease. Experts at Northern Care Alliance NHS Foundation Trust (NCA) say the research study is a major milestone for the inherited condition. They...
treatment News
FORT LEE, N.J. – Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, announced that the first patient has been treated in the KIDCARES10 (KIg10 in peDiatric subjects: effiCacy, sAfety and phaRmacokinEticS of a 10% IG) clinical trial. The...
MILAN, Italy – Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, announced today that detailed results of the first phase III clinical trial of safinamide as adjunctive treatment in mid- to late-stage Parkinson’s disease (PD) (Study 016), conducted with its partner Merck...
West Des Moines, Iowa – Born in 2013, identical twins Kenzie and Kaylie Morell were hitting some, if not all, of their normal infant and toddler milestones—until they began to slip back from them. When Kenzie was around 15 months old, she started to regress. Kaylie followed a year and...
BEIJING & CAMBRIDGE, Mass. – CANbridge Pharmaceuticals, Inc., a biopharmaceutical company developing and commercializing innovative drugs to treat rare diseases and targeted cancers in China and globally, announced that the first subject has been dosed in the Phase I trial of CAN106 in Singapore, which is being developed for the...
CAMBRIDGE, Mass. — Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other diseases, announced the presentation of data regarding the Phase 1 clinical trial design of FX-909, a highly potent and selective inhibitor of PPARG. “FlareTx has built a robust body...
CARY, N.C. — Focal Medical, Inc., a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003,...
TAIPEI — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announces that the first patient has been dosed in the Casppian Phase 3 registration study. “The Casppian Phase 3 study is an open-label, multicenter clinical trial to evaluate the efficacy, safety, and pharmacokinetics of leuprolide (FP-001) 42 mg-controlled release in patients with...
TAIPEI, Taiwan — Foresee Pharmaceuticals (TPEx: 6576), announced the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee Pharmaceuticals continue the trial with a minor amended protocol. The Casppian Phase 3 study is an open-label, multicenter,...
TAIPEI— Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) announced today that the company will be presenting at the American Heart Association (AHA) 2023 Annual Meeting taking place in Philadelphia, PA, from November 11-13, 2023. The presentation will focus on Foresee’s first-in-class oral ALDH2 activator, FP-045, and the clinical design of Phase 2...